Bevacizumab-irdye800cw (Not yet branded)
Other Medications
Description
Bevacizumab-IRDye800CW is a fluorescent imaging agent that combines the anti-VEGF monoclonal antibody bevacizumab with the near-infrared fluorescent dye IRDye800CW. This compound is designed for real-time visualization and detection of colorectal tumors during endoscopic procedures. The agent enables surgeons and gastroenterologists to identify tumor tissue through fluorescence-guided imaging, particularly useful in detecting rectal cancer and adenomatous polyps in patients with familial adenomatous polyposis.
Mechanism of Action
The bevacizumab component specifically binds to vascular endothelial growth factor (VEGF), which is overexpressed in colorectal tumors and their associated blood vessels. Once bound to VEGF-rich tumor tissue, the conjugated IRDye800CW emits near-infrared fluorescence when excited by specific wavelengths of light. This fluorescent signal allows for real-time visualization of tumor margins and vascular structures during endoscopic examination.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.